How to Read Dihexa COA — Lab Report Breakdown

A 2023 independent analysis of research peptides purchased from 47 suppliers found that 31% contained purity levels below the advertised specification. Some by more than 15 percentage points. The only way researchers identified these discrepancies was by cross-referencing the supplier's Certificate of Analysis against third-party verification. Without that COA, there's no practical method to confirm what's actually in the vial.

Our team has guided researchers through peptide sourcing protocols for years. The gap between a usable COA and a misleading one comes down to three data points most suppliers hope you won't scrutinise: HPLC purity percentage, mass spectrometry confirmation, and endotoxin levels.

How do you verify peptide quality from a Certificate of Analysis?

A Certificate of Analysis (COA) for Dihexa confirms three critical quality markers: HPLC purity percentage (target ≥98%), mass spectrometry molecular weight match (expected 880.03 Da for Dihexa), and endotoxin contamination level (must be <10 EU/mg for research use). These three data points verify that the peptide matches its chemical identity, contains minimal synthesis byproducts, and won't trigger immune responses in biological systems.

Most researchers assume the COA validates quality automatically. It doesn't. A COA only proves what the lab tested for and how those tests were conducted. Suppliers can choose which assays to run, which detection limits to report, and whether to include batch-specific data or generic reference ranges. The rest of this piece covers how to read each section of a Dihexa COA, what acceptable ranges look like for research-grade peptides, and which red flags indicate a peptide won't perform as expected in experimental protocols.

Step 1: Verify HPLC Purity Percentage and Chromatogram Baseline

The HPLC purity value tells you what percentage of the sample is the target peptide versus synthesis byproducts, truncated sequences, or residual solvents. Research-grade Dihexa should show ≥98% purity by HPLC. Anything below 95% suggests incomplete purification or peptide degradation during storage.

The chromatogram itself matters as much as the percentage. A clean HPLC trace shows one dominant peak (the target peptide) with a smooth baseline and minimal secondary peaks. If the chromatogram displays multiple peaks of similar height, the sample contains significant impurities even if the stated purity is high. Peak integration methods can be manipulated to exclude certain contaminants from the final percentage. Look for a single sharp peak that accounts for ≥98% of the total integrated area under the curve.

Our experience reviewing COAs from multiple peptide suppliers shows that baseline noise is the clearest quality differentiator. A noisy baseline with erratic fluctuations indicates detector drift, column degradation, or sample contamination. Any of which compromise the accuracy of the purity measurement. Real Peptides provides batch-specific HPLC chromatograms with every COA, allowing researchers to assess baseline stability and peak resolution before committing to a compound for experimental use.

Step 2: Confirm Molecular Weight Match Through Mass Spectrometry

HPLC purity alone doesn't prove identity. A contaminated sample can still show high purity if the contaminant elutes at the same retention time as the target peptide. Mass spectrometry (MS) confirms that the molecular weight matches the expected value for Dihexa: 880.03 Da (or 881.04 Da for the protonated species [M+H]⁺).

The acceptable margin of error for peptide MS is ±0.5 Da for electrospray ionisation (ESI) and ±1 Da for MALDI-TOF instruments. If the reported molecular weight deviates by more than 1 Da, the peptide likely contains sequence errors, post-translational modifications, or salt adducts that alter its biological activity. A COA that lists molecular weight as 'confirmed' without showing the actual measured value should be treated as incomplete. You're verifying data, not trusting a checkbox.

MS also reveals whether the peptide exists as a single clean species or as a mixture of fragments and aggregates. A high-resolution MS spectrum should display the target peak as the base peak (100% relative intensity) with no competing peaks above 10% intensity. Multiple peaks of similar intensity suggest incomplete coupling during synthesis or peptide cleavage during purification. Both of which reduce the effective concentration of active compound in the vial.

Step 3: Assess Endotoxin Level and Sterility for In Vivo Use

Endotoxin contamination (lipopolysaccharides from bacterial cell walls) triggers inflammatory responses in cell cultures and animal models, confounding experimental results even at concentrations below 10 EU/mg. For in vitro studies, endotoxin levels should be <10 EU/mg. For in vivo administration, the threshold drops to <5 EU/mg to prevent immune activation that mimics or masks the peptide's intended effects.

The COA should specify the assay method used to measure endotoxin: LAL (Limulus Amebocyte Lysate) is the standard for peptides intended for biological research. Generic statements like 'low endotoxin' or 'endotoxin tested' without a numerical value are insufficient. You need the exact EU/mg figure to calculate acceptable dosing limits for your protocol.

Sterility testing is distinct from endotoxin testing. A peptide can be sterile (no live bacteria present) but still contain high endotoxin levels from bacterial debris introduced during synthesis or lyophilisation. If the COA lists sterility as 'N/A' or omits it entirely, the peptide hasn't been tested for microbial contamination and shouldn't be used in cell culture or in vivo experiments without additional sterilisation steps.

How to Read Dihexa COA: Analytical Method Comparison

Key Takeaways

• HPLC purity for research-grade Dihexa should be ≥98%, with a single dominant peak on the chromatogram and minimal baseline noise indicating clean separation and detector stability.
• Mass spectrometry confirms peptide identity by matching molecular weight to the expected 880.03 Da. HPLC alone cannot distinguish structurally similar compounds or detect sequence errors.
• Endotoxin levels must be <10 EU/mg for in vitro work and <5 EU/mg for in vivo protocols, measured by LAL assay and reported as a numerical value, not a generic 'low' statement.
• Sterility testing (USP <71>) is distinct from endotoxin testing and is required for any peptide used in cell culture or animal models to prevent microbial contamination of experimental systems.
• A complete COA includes batch-specific data for HPLC, mass spec, endotoxin, and sterility. Generic reference ranges or 'available upon request' statements indicate incomplete quality verification.
• Baseline noise in the HPLC chromatogram is the clearest quality differentiator across suppliers. Erratic fluctuations suggest detector issues or sample contamination that compromise purity accuracy.

What If: Dihexa COA Scenarios

What if the COA shows 97% purity instead of ≥98%?

Use the peptide for preliminary screening or dose-response studies where minor impurities won't confound results, but not for mechanistic studies requiring precise compound identity. The 1–2% impurity likely consists of truncated sequences or acetylated variants that don't bind the target receptor with the same affinity as full-length Dihexa. If your protocol depends on exact receptor occupancy or kinetic measurements, source a higher-purity batch. The cost difference is negligible compared to the risk of attributing off-target effects to the primary compound.

What if mass spectrometry shows 881.5 Da instead of 880.03 Da?

Verify whether the supplier reported the protonated species [M+H]⁺ (expected 881.04 Da) or the neutral molecule (880.03 Da). This distinction accounts for the mass difference and is standard practice in ESI-MS. If the reported value is 881.5 Da or higher, the peptide likely contains a sodium adduct ([M+Na]⁺) or other salt complex that adds 22–23 Da to the molecular weight. Sodium adducts don't necessarily indicate poor quality, but they do affect solubility and dosing calculations because the effective peptide concentration is lower than the stated mg/vial value would suggest.

What if the endotoxin level is listed as '<0.1 EU/mg' with no upper detection limit?

This is the ideal scenario. It confirms the peptide was tested with a sensitive LAL assay and falls well below the threshold for both in vitro and in vivo use. Values this low indicate the peptide was synthesised and purified under endotoxin-controlled conditions, not just tested after the fact. For comparison, most research-grade peptides report endotoxin as <5–10 EU/mg, so a reading of <0.1 EU/mg suggests rigorous depyrogenation during manufacturing.

The Unfiltered Truth About Dihexa COA Interpretation

Here's the honest answer: most COAs are formatted to pass a compliance check, not to inform experimental decisions. Suppliers know that fewer than 10% of researchers will cross-reference the chromatogram against the stated purity, verify that the molecular weight was measured (not just 'confirmed'), or question why sterility testing is listed as 'N/A' for a peptide intended for cell culture.

The peptide industry operates on trust because independent third-party verification is prohibitively expensive for individual researchers. A full reanalysis of purity, identity, and endotoxin through an accredited lab costs $800–1,200 per sample. More than most labs spend on the peptide itself. This creates an environment where supplier integrity is the only quality control mechanism that matters. If the COA doesn't include batch-specific HPLC chromatograms, numerical endotoxin values, and measured molecular weight data, you're being asked to trust the supplier's internal quality standards without evidence.

We mean this sincerely: a supplier who provides incomplete COAs isn't necessarily selling bad peptides. But they are selling peptides without accountability. The difference between a $150 vial and a $90 vial is often the documentation, not the compound.

A COA is only as reliable as the lab that generated it and the supplier who chose which tests to run. Batch-specific data from an ISO-certified analytical facility gives you verifiable proof of quality. Generic reference ranges or placeholder statements like 'meets specifications' tell you nothing about the specific vial you're about to use in a six-month study. If the supplier won't provide complete analytical data upfront, assume the peptide quality reflects that same reluctance to commit to measurable standards. Real Peptides publishes full batch-specific COAs with every order. Not because it's required, but because complete transparency is the only defensible approach to peptide sourcing for serious research.